Company news
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) news
Werewolf Therapeutics, Inc. news releases on 6ix. Latest, Aug 11, 2022: Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides…
Press releases — page 2
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
August 10, 2022
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 9, 2022
Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting
April 7, 2022
Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights
March 23, 2022
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment
March 15, 2022
Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
March 14, 2022
Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
November 9, 2021
Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors
October 27, 2021
Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program
August 17, 2021
Werewolf Therapeutics Reports Second Quarter 2021 Financial Results and Business Update
August 11, 2021
Werewolf Therapeutics Announces Its Addition to the Russell 2000® Index
June 23, 2021
Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer
June 14, 2021
Werewolf Therapeutics Reports First Quarter 2021 Financial Results
June 9, 2021
Werewolf Therapeutics Appoints Mike Sherman to its Board of Directors
May 27, 2021
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
April 28, 2021